ASSESSMENT COST-EFFECTIVENESS OF PEGFILGRASTIM AND FILGRASTIM IN PEDIATRIC PATIENTS WITH SOLID TUMORS
Author(s)
Medina Barajas FP1, Sánchez Zubieta F2, Islas Carbajal MC3, Pardo Zepeda M1, Ramírez Urenda X2, Rincón Sánchez AR3
1Universidad de Guadalajara, Guadalajara, Mexico, 2Hospital Civil de Guadalajara, Guadalajara, Mexico, 3CUCS, Universidad de Guadalajara, Guadalajara, Mexico
OBJECTIVES: Evaluate the cost- effectiveness of pegfilgrastim compared with filgrastim relationship in preventing febrile neutropenia in pediatric patients with solid tumors. METHODS: Retrospective cohort study from 2012 to 2014, and was made micro-cost technic. Records of pediatric patients diagnosed with solid tumors receiving pegfilgrastim and filgrastim post-chemotherapy for prevention of febrile neutropenia were evaluated. Febrile neutropenia is considered as an event with absolute neutrophil count less than 1000 cells per milliliter blood and fever ≤ 38.2°C. This study adheres to the principles of the Declaration of Helsinki, followed good clinical practices and has been approved by Hospital bioethics committee. RESULTS: CONCLUSIONS: Filgrastim maintains effective cost advantage over pegfilgrastim when the dose is less than 200 micrograms in a treatment period of at least 7 days
Conference/Value in Health Info
2014-05, ISPOR 2014, Palais des Congres de Montreal
Value in Health, Vol. 17, No. 3 (May 2014)
Code
PCN113
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Oncology